Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2017-04-04 | Dr. Ferrante, a hematologist-oncologist, most recently served as Chief Medical Officer and Head of Research and Development at Tokai Pharmaceuticals and brings over 20 years of oncology drug development experience to the Board. |
| 2018-04-06 | Dr. Ferrante, a hematologist-oncologist, most recently served as Chief Medical Officer and Head of Research and Development at Tokai Pharmaceuticals and brings over 20 years of oncology drug development experience to the Board. |
| 2019-04-05 | Dr. Ferrante holds an M.D. from Georgetown University... Based on Dr. Ferrante’s depth of experience in the biotechnology industry... the Board believes Dr. Ferrante has the appropriate set of skills to serve as a member of our Board. |
| 2020-04-03 | Dr. Ferrante has served as a director since January 2017. Dr. Ferrante, a hematologist-oncologist, most recently served as Chief Medical Officer and Head of Research and Development at Tokai Pharmaceuticals and brings over 25 years of oncology drug development experience to the Board. |
| 2021-04-02 | Dr. Ferrante, a hematologist-oncologist, most recently served as Chief Medical Officer and Head of Research and Development at Tokai Pharmaceuticals and brings over 25 years of oncology drug development experience. |
| 2022-04-08 | Dr. Ferrante holds an M.D. from Georgetown University and completed her internship and residency in internal medicine at New England Deaconess Hospital (now part of Beth Israel Deaconess Medical Center) followed by a fellowship in hematology and oncology. |
| 2023-04-17 | Dr. Ferrante holds an M.D. from Georgetown University. |
Data sourced from SEC filings. Last updated: 2026-02-03